Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Quidel (NASDAQ:QDEL) Corporation’s stock reached a 52-week low, closing at $23.75, with a market capitalization of $1.6 billion. This marks a significant downturn for the company, which has experienced a 42.83% decrease in its stock value over the past year. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with analysts setting price targets ranging from $27 to $60. The decline reflects ongoing challenges and market conditions impacting the company’s performance, with a year-to-date return of -45.48% and a concerning debt-to-capital ratio of 0.62. This new low underscores the volatility and pressures faced by Quidel in the current economic climate, as investors react to broader market trends and company-specific developments. InvestingPro subscribers can access 8 additional key insights about Quidel’s financial health and future prospects through the comprehensive Pro Research Report.
In other recent news, QuidelOrtho reported strong financial results for Q1 2025, with adjusted earnings per share of $0.74, beating the forecasted $0.61. The company’s revenue reached $693 million, just shy of the expected $694.43 million. In a strategic move, QuidelOrtho announced plans to acquire LEX Diagnostics, pending FDA approval, and discontinue its Savanna platform. The acquisition is expected to enhance their molecular diagnostics offerings, with LEX Diagnostics’ PCR capabilities for Flu A/B and COVID-19 anticipated to launch in early 2026.
Citi analysts maintained their Buy rating on Quidel stock, setting a price target of $50.00, reflecting confidence in the company’s strategic pivot. Jefferies analyst Tycho Peterson also upgraded Quidel’s stock rating to Buy, with a price target of $44.00, citing improvements in EBITDA margins and strategic initiatives. The company has shown signs of an early turnaround, with plans to mitigate tariff exposure and aim for growth in China. These developments highlight QuidelOrtho’s ongoing efforts to realign its product portfolio and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.